Wyeth Vaccines GM James Connolly: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec outlines Wyeth’s aim to double sales of the Prevnar franchise in the next five years, pipeline opportunities and vaccine pricing.
You may also be interested in...
Novartis Unveils Promising Phase II Data For Meningitis B Vaccine
Data show dosing series produces protective immune response in infants.
Novartis Unveils Promising Phase II Data For Meningitis B Vaccine
Data show dosing series produces protective immune response in infants.
Why Wyeth's Talking Up Vaccines
Given the near-term generic threats to over a third of its US drug revenues and two late-stage set-backs last year, Wyeth's vaccines business--basically the $3 billion-and-growing pneumococcal vaccine Prevnar--matters more than ever before. So, then, does eliminating an imminent competitive threat from GlaxoSmithKline, and a swift switch to follow-on Prevnar 13 in 2010. Indeed, vaccine chiefs at the other four big players-Sanofi-Aventis, Merck & Co. Inc., GlaxoSmithKline PLC, and Novartis AG-are likely to become more prominent, too. Vaccines may still account for only a small minority of revenues at these Big Pharma, but most saw far healthier growth in their vaccines business in 2007 than in therapeutics. That's why Sanofi, according to recent media reports, is out looking for vaccine acquisitions.